Data Driven Analysis to Drive our Understanding of Placebo Responses in Neuropsychiatric Drug Development

Time: 12:05 pm
day: Day One


  • Very few genetic studies have been conducted to understand individual-specific placebo response and are limited due to a lack of no-treatment control groups, using samples with heterogeneous therapeutic experiences, and relatively small sample sizes
  • We explore and identify the challenges in Identifying genetic factors associated with individual-specific placebo response through genome-wide hypothesis-free studies on samples collected from placebo arms in CNS trials
  • We leverage polygenic risk scores computed from large bio-banking efforts like the UKBiobank to identify risk factors that differentiate placebo responders from non-responders
  • Discuss new approaches in analyzing response in psychiatric clinical trials and other data collection efforts to accommodate the complexity of the phenotype.